학술논문
Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for Fc[gamma]RIIIb and MHC class II expression on the phagocytotic neutrophils
Document Type
Academic Journal
Author
Source
Experimental Hematology. March, 2009, Vol. 37 Issue 3, p309, 13 p.
Subject
Language
English
ISSN
0301-472X
Abstract
To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.exphem.2008.11.006 Byline: Mami Shibata-Koyama, Shigeru Iida, Hirofumi Misaka, Katsuhiro Mori, Keiichi Yano, Kenya Shitara, Mitsuo Satoh Abstract: Antibody-dependent cellular cytotoxicity mediated by natural killer cells via leukocyte receptor IIIa (Fc[gamma]RIIIa) is greatly enhanced by the absence of the core fucose of Fc oligosaccharides, and is closely related to the clinical efficacy of anticancer processes in humans in vivo. Here, we focused on the physiological functions of nonfucosylated anti-CD20 IgG1 rituximab, in particular those functions mediated by human neutrophils, which highly express Fc[gamma]RIIIb, a highly homologous Fc[gamma]R to Fc[gamma]RIIIa. Author Affiliation: Tokyo Research Laboratories, Kyowa Hakko Kogyo Co., Ltd., Machida-shi, Tokyo, Japan Article History: Received 3 July 2008; Revised 8 September 2008; Accepted 12 November 2008